Industry Briefs: October 8, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: October 8, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Accupac has announced that it is doubling its capacity and expanding its manufacturing capabilities with a 221,000-ft2 addition of its facility in Lakewood, New Jersey. Read More

Almac has expanded its MHRA/FDA-approved, United Kingdom commercial-packaging facility with the acquisition of a Noack N 623 blister-packaging line from Romaco. Read More

In other news, Almac and DSM have signed collaboration agreement in biocatalysis to provide manufacturing services to the pharmaceutical industry. Read More

Bend Research and the Dow Chemical Company have formed an exclusive collaboration to provide science-based, spray-dried dispersion solutions and select enabling new polymers for poorly soluble oral drugs. Read More

Dr. Reddy’s has announced an expansion in the areas of activated mPEG manufacturing and in the development and manufacture of APIs for use in preclinical through to commercial development at its manufacturing facility in Mirfield, United Kingdom. Read More

Encap Drug Delivery and the School of Pharmacy, Queen’s University Belfast have received funding from the Technology Strategy Board and the Scottish Government that will allow both to enter into a collaborative Knowledge Transfer Partnership on hot-melt extrusion. Read More

Mucosis, a Dutch clinical-stage biotechnology company, has signed a research and license option agreement with Crucell Holland, a Dutch developer of vaccines and antibodies. Read More

Oxford PharmaGenesis has opened a new facility in Switzerland. Read More

Penn Pharma underwent a successful FDA inspection at its Tredegar, United Kingdom facility. Read More

Sanofi and Massachusetts General Hospital have launched a collaboration aimed at furthering translational medicine research to develop new treatments for various types of hematological malignancies and solid tumors. Read More

People News

Pharmanet/I3 has appointed Jamil Hantash as director of immunochemistry operations. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here